About UPF0764 protein C16orf89
UPF0764 protein C16orf89 (C16orf89) is a protein
from Homo sapiens identified by UniProt accession
Q6UX73, 402 residues long.
MolForge cross-references it against 0 known binders and
25 disease associations.
Target properties
| Protein name | UPF0764 protein C16orf89 |
| UniProt accession | Q6UX73 |
| Gene | C16orf89 |
| Organism | Homo sapiens |
| Length | 402 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (25)
Diseases linked to this target (Open Targets).
- neurofibrillary tangles measurement · score 0.10
- 22q11.2 deletion syndrome · score 0.05
- gastric carcinoma · score 0.04
- 8p23.1 microdeletion syndrome · score 0.04
- attention deficit hyperactivity disorder · score 0.04
- hypoparathyroidism, familial isolated, 2 · score 0.04
- Barrett's esophagus · score 0.03
- dilated cardiomyopathy 1I · score 0.03
- Primary hypomagnesemia with secondary hypocalcemia · score 0.03
- blood protein measurement · score 0.03
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q6UX73-F1 | alphafold | PREDICTED | 71.06 | — |
Amino-acid sequence (402 residues)
MASLGLLLLL LLTALPPLWS SSLPGLDTAE SKATIADLIL SALERATVFL EQRLPEINLD GMVGVRVLEE QLKSVREKWA QEPLLQPLSL RVGMLGEKLE AAIQRSLHYL KLSDPKYLRE FQLTLQPGFW KLPHAWIHTD ASLVYPTFGP QDSFSEERSD VCLVQLLGTG TDSSEPCGLS DLCRSLMTKP GCSGYCLSHQ LLFFLWARMR GCTQGPLQQS QDYINLFCAN MMDLNRRAEA IGYAYPTRDI FMENIMFCGM GGFSDFYKLR WLEAILSWQK QQEGCFGEPD AEDEELSKAI QYQQHFSRRV KRREKQFPDS RSVAQAGVQW RNLGSLQPLP PGFKQFSCLI LPSSWDYRSV PPYLANFYIF LVETGFHHVA HAGLELLISR DPPTSGSQSV GL
Explore UPF0764 protein C16orf89 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets